Мупироцин: клиническое применение

1. Баландин А.Б.,  Димова А.Д. Рациональный выбор антибиотика для местного применения у больных наружным отитом и фурункулами слухового прохода. Вестн. оториноларингологии. 2004; 2: http://www.mediasphera.ru/journals/oto/detail/127/1556/
2. Белькова Ю.А. Пиодермии в амбулаторной практике. Клин. микробиол. антимикроб. химиотер. 2005; 7: 255–70.
3. Белькова Ю.А., Страчунский Л.С., Кречикова О.И. и др. Сравнительная эффективность 0,75% мази хлорамфеникола и 2% мази мупироцина при лечении в амбулаторных условиях взрослых пациентов с инфекциями кожи и мягких тканей. Клин. микробиол. антимикроб. химиотер. 2007; 1: 57–65.
4. Богданович Т.М., Страчунский Л.С. Мупироцин: уникальный антибиотик для местного применения. Клин. микробиол. антимикроб. химиотер. 1999; 1: 57–65.
5. Дехнич А.В., Эйдельштейн И.А., Нарезкина А.Д. и др. Эпидемиология антибиотикорезистентности нозокомиальных штаммов Staphylococcus aureus в России: результаты многоцентрового исследования. Клин. микробиол. антимикроб. химиотер. 2002; 4: 325–36.
6. Михайлов И.Б. Основы фармакотерапии детей и взрослых: руководство для врачей. М.: АСТ, 2005.
7. Страчунский Л.С., Дехнич А.В., Белькова Ю.А. Сравнительная активность антибактериальных препаратов, входящих в лекарственные формы для местного применения, в отношении Staphylococcus aureus: результаты российского многоцентрового исследования. Клин. микробиол. антимикроб. химиотер. 2002; 2: 157–63.
8. Alcaide VMJ, Cabrera HR, Calero RJ. Efficacy of a broad-spectrum antibiotic (mupirocin) in an in vitro model of infected skin. Burns 1993; 19: 392–5.
9. Allon M. Dialysis catheter-related bacteremia: treatment and prophylaxis. Am J Kidney Dis 2004; 44: 779–91.
10. Annigeri R, Conly J, Vas S et al. Emergence of mupirocinresistant Staphylococcus aureus in chronic peritoneal dialysis patients using mupirocin prophylaxis to prevent exit-site infection. Perit Dial Int 2001; 21: 554–9.
11. Barton LL, Friedman AD, Sharkey AM et al. Impetigo contagiosa III. Comparative efficacy of oral erythromycin and topical mupirocin. Pediatr Dermatol 1989; 6: 134–8.
12. Bass JW, Chan DS, Creamer KM et al. Comparison of oral cephalexin, topical mupirocin and topical bacitracin for treatment of impetigo. Pediatr Infect Dis J 1997; 16: 708–10.
13. Bertrand X, Slekovec C, Talon D. Use of mupirocin–chlorhexidine treatment to prevent Staphylococcus aureus surgical site infections. Future Microbiol 2010; 5: 701–3.
14. Bode LGM, Kluytmans JAJW, Wertheim HFL et al. Preventing surgical site infections in nasal carriers of Staphylococcus aureus. N Engl J Med 2010; 362: 9–17.
15. Boyce ST, Warden GD, Holder IA. Cytotoxicity testing of topical antimicrobial agents on human keratinocytes and fibroblasts for cultured skin grafts. J Burn Care Rehabil 1995; 16: 97–103.
16. Breen JO. Skin and soft tissue infections in immunocompetent patients. Am Fam Physician 2010; 81: 893–9.
17. Bruns DE, Herold DA, Rodeheaver GT, Edlich RF. Polyethylene glycol intoxication in burn patients. Burns 1992; 9: 49–52.
18. Burkart JM. Significance, epidemiology, and prevention of peritoneal dialysis catheter infections. Perit Dial Int 1996; 16: 340–6.
19. Casewell MW, Hill RLR. Elimination of nasal carriage of Staphylococcus aureus with mupirocin («pseudomonic acid») – a controlled study. J Antimicrob Chemother 1986; 17: 365–37.
20. Chain EB, Mellows G. Pseudomonic acid. Part 3. Structure of pseudomonic acid B. J Chem Soc Perkin Trans 1977; 1: 318–24.
21. Clayton J. The structure and configuration of pseudomonic acid C. Tetrahedron Letters 1980; 21: 88.
22. Dagan R, Bar-David Y. Double-blind study comparing erythromycin and mupirocin for treatment of impetigo in children. Antimicrob Agents Chemother 1992; 36: 287–90.
23. Darmstadt GL, Lane AT. Impetigo: an overview. Pediatr Dermatol 1994; 11: 293–303.
24. Deshpande LM, Fix AM, Pfaller MA, Jones RN. Emerging elevated mupirocin resistance rates among staphylococcal isolates in the SENTRY antimicrobial surveillance program (2000): correlations of results from disk diffusion, Etest and reference dilution methods. Diagn Microbiol Infect Dis 2002; 42: 283–90.
25. El Ferghani N. An open study of mupirocin in Libyan patients with skin infections. J Int Med Res 1995; 23: 508–17.
26. Ellis MW, Griffith ME, Dooley DP et al. Targeted intranasal mupirocin to prevent colonization and infection by community-associated methicillin-resistant Staphylococcus aureus strains in soldiers: a cluster randomized controlled trial. Antimicrob Agents Chemother 2007; 51: 3591–88.
27. Epstein NE. Preoperative, intraoperative, and postoperative measures to further reduce spinal infections. Surg Neurol Int 2011; 2: www.surgicalneurologyint.com.
28. Flowers RH, Schwenzer KJ, Kopel RF et al. Efficacy of an attachable subcutaneous cuff for the prevention of intravascular catheter-related infection: a randomized, controlled trial. JAMA 1989; 261: 878–83.
29. Fuchs PC, Jones RN, Barry AL. Interpretative criteria for disc diffusion susceptibility testing of mupirocin, a topical antibiotic. J Clin Microbiol 1990; 28: 608–9.
30. Fuller AT, Mellows G, Woodford M et al. Pseudomonic acid: an antibiotic produced by Pseudomonas fluorescens. Nature 1971; 234: 416–7.
31. Gales AC, Andrade SS, Sader HS, Jones RN. Activity of mupirocin and 14 additional antibiotics against staphylococci isolated from Latin American hospitals: report from the SENTRY antimicrobial surveillance program. J Chemother 2004; 16: 323–8.
32. Gilbert M. Topical 2% mupirocin versus 2% fusidic acid ointment in the treatment of primary and secondary skin infections. J Am Acad Dermatol 1989; 20: 1083–7.
33. GlaxoSmithKline. Bactroban (mupirocin) ointment 2% for dermatologic use prescribing information. Research Triangle Park, NC. 2001, Nov.
34. Haslund P, Bangsgaard N, Jarlov JO et al. Staphylococcus aureus and hand eczema severity. Br J Dermatol 2009; 161: 772–7.
35. Hughes J, Mellows G. Inhibition of isoleucyl-transfer ribonucleic acid synthetase in Echerichia coli by pseudomonic acid. Biochem J 1978; 176: 305–18.
36. Hughes J, Mellows G. On the mode of action of pseudomonic acid: inhibition of protein synthesis in Staphylococcus aureus. J Antibiot 1978; 31: 330–5.
37. Janagisawa T, Lee JT, Wu HC, Kawakami M. Relationship of protein structure of isoleucyl tRNA synthetase with pseudomonic acid resistance of Escherichia coli. A proposed mode of action of pseudomonic acid as an inhibitor of isoleucyl tRNA synthetase. J Biol Chem 1994; 269: 24304–9.
38. Jasuja K, Gupta SK, Arora DR, Gupta V. Bacteriology of primary pyodermas and comparative efficacy of topical application of mupirocin and sodium fusidate ointments in their treatment. Indian J Dermatol Venereol Leprol 2001; 67: 132–4.
39. Kerr M. Mupirocin resistance common in MRSA patients. Clin Infect Diseases 2007; 45: 541–7.
40. Koning S, Verhagen AP, Suijlekom-Smit van LWA et al. Interventions for impetigo. Cochrane Database of Systematic Reviews 2003, Issue 2. Art. No.: CD003261. DOI: 10.1002/14651858.CD003261.pub2.
41. Kraus SJ, Eron LJ, Bottenfield GW et al. Mupirocin cream is as effective as oral cephalexin in the treatment of secondarily infected wounds. J Farm Pract 1998; 47: 429–33.
42. Langdon CG, Mahapatra KS. Efficacy and acceptability of fusidic acid cream and mupirocin ointment in acute skin sepsis. Curr Ther Res 1990; 48: 174–9.
43. Leigh DA, Joy C. Treatment of familial staphylococcal infection – comparison of mupirocin nasal ointment and chlorhexidine/
neomycin (Naseptin) cream in eradication of nasal carriage. J Antimicrob Chemoter 1993; 31: 909–17.
44. Leyden JJ. Studies on the safety of Bactroban ointment: potential for contact allergy, contact irritation, phototoxicity and photoallergy. Bactroban (Mupirocin). Excerp Med Cur Clin Pract Ser 1985; 16.
45. Leyden JJ. Mupirocin: a new topical antibiotic. Semin Dermatol 1987; 6: 48–54.
46. Leyden JJ. Review of mupirocin ointment in the treatment of impetigo. Clin Pediatr (Phila) 1992; 31: 549–53.
47. Leyden JJ. Therapy for acne vulgaris. New Engl J Med 1997; 336: 1156–62.
48. Lim CT, Wong KS, Foo MW. The impact of topical mupirocin on peritoneal dialysis infection in Singapore General Hospital. Nephrol Dial Transplant 2005; 20: 2202–6.
49. Lobbedez T, Gardam M, Dedier H et al. Routine use of mupirocin at the peritoneal catheter exit site and mupirocin resistance: still low after 7 years. Nephrol Dial Transplant 2004; 19: 3140–3.
50. Maki DG, Band JDA comparative study of polyantibiotic and iodophor ointments in prevention of vascular catheter-related infection. Am J Med 1981; 70: 739–44.
51. McCann M, Moore ZEH. Interventions for preventing infectious complications in haemodialysis patientswith central venous catheters. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD006894. DOI: 10.1002/14651858.CD006894.pub2.
52. Morley PAR., Munot LD. A comparison of sodium fusidate ointment and mupirocin ointment in superficial skin sepsis. Curr Med Res Opin 1988; 11: 142–8.
53. Moura JP, Pimenta FC, Hayashida M et al. Colonization of nursing professionals by Staphylococcus aureus. Rev Latino-Am Enfermagem 2011; 19: 325–31.
54. Nicholas RO, Berry V, Hunter PA, Kelly JA. The antifungal activity of mupirocin. J Antimicrob Chemother 1999; 43: 579–82.
55. O'Hanlon PJ, Rogers NH, Tyler JW. The chemistry of pseudomonic acid. Part 6. Structure and preparation of pseudomonic acid D. J Chem Soc, Perkin Trans 1983; 1: 2655–7.
56. Ohana N. Skin-isolated community-acquired Staphylococcus aureus: in vitro resistance to methicillin and erythromycin. J Amer Acad Dermatol 1989; 3: 544–6.
57. Pappa KA. The clinical development of mupirocin. J Amer Acad Dermatol 1990; 22: 873–9.
58. Patel JB, Gorwitz RJ, Jernigan JA. Mupirocin resistance. Clin Infect Dis 2009; 49: 935–41.
59. Pearson ML. Guideline for prevention of intravascular device-related infections. Infect Control Hosp Epidemiol 1996; 17: 438–73.
60. Pedreau-Remington F, Stefanik D, Peters G et al. Methicillin-resistant Staphylococcus haemolyticus on the hands of health care workers: a route of transmission or a source? J Hosp Infect 1995; 31: 195–203.
61. Perez-Fontan M, Rosales M, Rodriguez-Carmona A et al. Mupirocin resistance after long-term use for Staphylococcus aureus colonization in patients undergoing chronic peritoneal dialysis. Am J Kidney Dis 2002; 39: 337–41.
62. Ed. Art. Prevention of surgical-site infections. N Engl J Med 2010; 362: 1540–4.
63. Reagan DR, Doebbeling BN, Pfaller MA. Elimination of coincident Staphylococcal aureus nasal and hand carriage with intranasal application of mupirocin calcium ointment. Ann Intern Med 1991; 114: 101–6.
64. Rijen van MM, Bonten M, Wenzel R, Kluytmans J. Mupirocin ointment for preventing Staphylococcus aureus infections in nasal carriers. Cochrane Database of Systematic Reviews 2008, Issue 4. Art.No.:CD006216. DOI: 10.1002/14651858.CD006216.pub2.
65. Rijen van MM, Kluytmans JA. New approaches to prevention of staphylococcal infection in surgery. Curr Opin Infect Dis 2008; 21: 380–4.
66. Rist T, Parish LC, Capin LR et al. A comparison of the efficacy and safety of mupirocin cream and cephalexin in the treatment of secondarily infected eczema. Clin Exp Dermatol 2002; 27: 14–20.
67. Rutherford KD, Kavanagh K, Parham K. Auditory function after application of ototopical vancomycin and mupirocin solutions in a murine model. Otolaryngol Head Neck Surg 2011; 144: 419–26.
68. Sawant S, Janaki VR, Mittal RR et al. Evaluation of safety and efficacy of Supirocin-B (Mupirocin 2% + Betamethasone Dipropionate 0,05%) in infected dermatosis – a post marketing study. JIMA 2000; 98: 2.
69. Scully BE, Briones F, Gu JW. Mupirocin treatment of nasal staphylococcal colonization. Arch Intern Med 1992; 152: 363–6.
70. Strippoli GFM, Tong A, Johnson DW et al. Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients. Cochrane Database of Systematic Reviews 2004, Issue 4. Art.No.: CD004679. DOI: 10.1002/14651858.CD004679.pub2.
71. Sutherland R, Boon RJ, Griffin KE. Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use. Antimicrob Agent Chemother 1985; 27: 495–8.
72. Sutton JB. Efficacy and acceptability of fusidic acid cream and mupirocin ointment in facial impetigo. Curr Ther Res 1992; 51: 673–8.
73. Tanaka K, Tamaki M, Watanabe S. Effect of furanomycin on the synthesis of isoleucyl-tRNA. Biochim Biophys Acta 1969; 195: 244–5.
74. Trilla A, Miro JM. Identifying high risk patients for Staphylococcus aureus infections: skin and soft tissue infections. J Chemother 1995; 7: 37–43.
75. Vas SI, Conly J, Bargman JM, Oreopoulos DG. Resistance to mupirocin: no indication of it to date while using mupirocin ointment for prevention of Staphylococcus aureus exitsite infections in peritoneal dialysis patients. Perit Dial Int 1999; 19: 313–4.
76. Villinger JW, Robertson WD, Kanji K et al. A comparison of the new topical antibiotic mupirocin ('Bactroban') with oral antibiotics in the treatment of skin infections in general practice. Curr Med Res Opin 1986; 10: 339–45.
77. White DG, Collins PO, Rowsell RB. Topical antibiotics in the treatment of superficial skin infections in general practice – a comparison of mupirocin with sodium fusidate. J Infect 1989; 18: 221–9.
78. Williford PM. Opportunities for mupirocin calcium cream in emergency department. J Emerg Med 1999; 17: 213–20.
79. Wong KS, Lim KB, Tham SN et al. Comparative double-blinded study between mupirocin and tetracycline ointments for treating skin infections. Siungapoore Med J 1989; 30: 380–3.

С.В.Оковитый, Д.Ю.Ивкин
Санкт-Петербургская государственная химико-фармацевтическая академия